WHAT IS CLAIMED IS:

ZLOT, et al.

1. An isolated or recombinant polynucleotide encoding an antigenic polypeptide comprising at least 17 contiguous amino acids from the mature polypeptide from:

- a) SEQ IN NO: 2; or
- b) SEQ ID NO: 5 or 7.
- 2. The polynucleotide of Claim 1, encoding a mature polypeptide from SEQ ID NO: 2, 5, or 7.
 - 3. The polynucleotide of Claim 1, which hybridizes at 55° C, less than 500 mM salt, and 50% formamide to the coding portions of SEQ NO: 1 or 4 or 6.
- The polynucleotide of Claim 3, comprising at least 35 contiguous nucleotides of the coding portion of SEQ ID NO: 1 or 4 or 6.
- 20 5. An expression vector comprising the polynucleotide of Claim 1.
 - 6. A host cell containing the expression vector of Claim 5, including a eukaryotic cell.
- 7. A method of making an antigenic polypeptide comprising expressing a recombinant polynucleotide of Claim 1.
- 30 8. A method for forming a duplex with a polynucleotide of Claim 1, comprising contacting said polynucleotide with a probe that hybridizes, under stringent conditions, to at least 25 contiguous nucleotides of the coding portion of SEQ ID NO: 1 or 4 or 6; thereby forming said duplex.

A kit for the detection of a polynucleotide of Claim 1, comprising a polynucleotide that hybridizes, under stringent hybridization conditions, to at least 17 contiguous nucleotides of a polynucleotide of Claim 1.

5

The kit of claim 9, wherein said probe is 10. detectably labeled.

A binding compound comprising an antibody binding 11. site which specifically binds to at least 17 contiguous amino acids from SEQ ID NO: 2 or 5 or 7.

The binding compound of Claim 11, wherein: 12.

- said antibody binding site is:
 - specifically immunoreactive with a 1) polypeptide of SEQ ID NO: 2 or 5 or 7;
 - raised against a purified or recombinantly 2) produced human DC-STAMP or DSP-1 protein; or
 - in a monoclonal antibody, Fab, or F(ab)2; or 3)

20

b)

1)

15

- said binding compound is: an antibody molecule;
 - a polyclonal antiserum; 2)
 - detectably labeled; 3)
 - sterile; or 4)

25

30

35

in a buffered composition. 5)

- A method using the binding compound of Claim 11, 13. comprising contacting said binding compound with a biological sample comprising an antigen, wherein said contacting results\in formation of a binding compound:antigen complex.
- The method of Claim 13, wherein said biological 14. sample is from a human, and wherein said binding compound is an antibody.

15

318. A detection kit comprising said binding compound of Claim 12, and:

a) instructional material for the use of said binding compound for said detection; or

b) a compartment providing segregation of said binding compound.

16. A substantially pure or isolated antigenic polypeptide, which binds to said binding composition of Claim 11 and further comprises at least 17 contiguous amino acids from SEQ ID NO: 2 or 5 or 7.

17. The polypeptide of Claim 16, which:

- a) comprises at least a fragment of at least 25 contiguous amino acid residues from a primate DC-STAMP or DSP-1 protein;
- b) is a soluble polypeptide;
- c) is detectably labeled;
- d) is in a step le composition;
- 20 e) is in a buffered composition;
 - f) binds to a cell surface receptor;
 - g) is recombinantly produced; or
 - h) has a naturally occurring polypeptide sequence.
- 25 18. The polypeptide of Claim 17, which comprises at least 17 contiguous amino acids of SEQ ID NO: 2 or 5 or 7.
- 19. A method of modulating physiology or development of a cell or tissue culture cells comprising contacting said cell with an agonist or antagonist of a primate DC-STAMP or DSP-1.

20. The method of Claim 19, wherein:

- a) said contacting is in combination with an agonist or antagon of Flt3 ligand; or
- b) said contacting is with an antagonist, including binding composition comprising an antibody binding site which specifically binds a DC-STAMP or DSP-1.

5